See more : Global Dining Holdings Limited (8496.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Acerus Pharmaceuticals Corporation (ASP.TO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acerus Pharmaceuticals Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Vodacom Group Limited (VOD.JO) Income Statement Analysis – Financial Results
- Exxon Mobil Corporation (XOM.MX) Income Statement Analysis – Financial Results
- Ningbo ZhongDa Leader Intelligent Transmission Co., Ltd. (002896.SZ) Income Statement Analysis – Financial Results
- JSW Holdings Limited (JSWHL.BO) Income Statement Analysis – Financial Results
- Atlas Copco AB (ATLPF) Income Statement Analysis – Financial Results
Acerus Pharmaceuticals Corporation (ASP.TO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.aceruspharma.com
About Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -4.13M | 1.09M | 3.77M | 7.38M | 6.44M | 24.49M | 16.92M | 4.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.12M | 2.01M | 2.20M | 10.32M | 3.26M | 4.45M | 5.11M | 9.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -5.25M | -929.00K | 1.57M | -2.95M | 3.18M | 20.03M | 11.81M | -4.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 127.05% | -85.62% | 41.64% | -39.95% | 49.36% | 81.81% | 69.80% | -113.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.56M | 2.53M | 2.83M | 2.40M | 2.17M | 1.60M | 2.87M | 9.05M | 22.68M | 16.52M | 13.16M | 0.00 | 0.00 |
| General & Administrative | 7.03M | 5.61M | 5.35M | 6.21M | 0.00 | 0.00 | 0.00 | 0.00 | 9.90M | 10.90M | 0.00 | 137.58K | 226.90K |
| Selling & Marketing | 13.95M | 12.27M | 4.78M | 2.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.97M | 17.88M | 10.13M | 8.46M | 0.00 | 0.00 | 0.00 | 0.00 | 9.90M | 10.90M | 0.00 | 137.58K | 226.90K |
| Other Expenses | 187.00K | -80.00K | 108.00K | 96.00K | 7.97M | 5.48M | 5.78M | 5.46M | 0.00 | 0.00 | 8.51M | 0.00 | 0.00 |
| Operating Expenses | 27.72M | 20.33M | 13.07M | 10.95M | 10.13M | 7.07M | 8.66M | 14.51M | 32.58M | 27.42M | 21.67M | 137.58K | 226.90K |
| Cost & Expenses | 28.84M | 22.34M | 15.27M | 21.28M | 13.40M | 11.53M | 13.76M | 23.70M | 32.58M | 27.42M | 21.67M | 137.58K | 226.90K |
| Interest Income | 8.00K | 67.00K | 17.00K | 12.00K | 21.00K | 17.00K | 129.00K | 94.00K | 116.29K | 14.06K | 160.33K | 0.00 | 0.00 |
| Interest Expense | 1.64M | 1.55M | 1.69M | 1.06M | 370.00K | 755.00K | 2.59M | 1.63M | 1.11M | 606.67K | 2.41M | 0.00 | 0.00 |
| Depreciation & Amortization | 681.00K | 1.01M | 1.12M | 1.95M | 2.05M | 2.21M | 2.41M | 2.57M | 1.17M | 983.69K | 851.02K | 0.00 | 0.00 |
| EBITDA | -31.50M | -21.86M | -13.32M | -15.74M | -6.25M | 14.38M | -4.42M | -18.45M | -30.00M | -26.54M | -22.75M | -137.58K | -226.90K |
| EBITDA Ratio | 762.09% | -2,015.02% | -353.40% | -213.42% | -97.02% | 58.74% | -26.15% | -427.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.18M | -21.26M | -11.50M | -13.90M | -6.95M | 12.96M | 3.15M | -19.39M | -32.58M | -27.42M | -21.67M | -137.58K | -226.90K |
| Operating Income Ratio | 778.56% | -1,959.08% | -305.20% | -188.44% | -107.88% | 52.92% | 18.63% | -449.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.64M | -3.17M | -4.63M | -4.86M | -1.72M | -1.54M | -12.57M | -3.26M | 302.37K | -715.35K | -4.34M | 0.00 | 0.00 |
| Income Before Tax | -33.82M | -24.42M | -16.13M | -18.76M | -8.67M | 11.42M | -9.42M | -22.65M | -32.27M | -28.13M | -26.01M | 0.00 | 0.00 |
| Income Before Tax Ratio | 818.22% | -2,251.06% | -428.05% | -254.26% | -134.50% | 46.63% | -55.70% | -525.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.64M | -1.62M | -2.94M | 29.00K | 47.00K | 300.00K | -390.00K | -1.63M | -320.00K | -110.98K | 371.91K | 137.58K | 226.90K |
| Net Income | -35.46M | -24.42M | -16.13M | -18.79M | -8.71M | 11.12M | -9.03M | -22.65M | -31.95M | -28.02M | -26.38M | -137.58K | -226.90K |
| Net Income Ratio | 857.88% | -2,251.06% | -428.05% | -254.66% | -135.23% | 45.41% | -53.39% | -525.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.61 | -16.70 | -11.03 | -14.59 | -7.13 | 9.27 | -7.84 | -22.37 | -42.73 | -56.39 | -68.61 | -159.79 | -263.53 |
| EPS Diluted | -4.61 | -16.70 | -11.03 | -14.59 | -7.13 | 9.21 | -7.84 | -22.37 | -42.73 | -56.39 | -68.61 | -159.79 | -263.53 |
| Weighted Avg Shares Out | 7.69M | 1.46M | 1.46M | 1.29M | 1.22M | 1.20M | 1.15M | 1.01M | 747.80K | 497.00K | 384.48K | 861.00 | 861.00 |
| Weighted Avg Shares Out (Dil) | 7.69M | 1.46M | 1.46M | 1.29M | 1.22M | 1.21M | 1.15M | 1.01M | 747.80K | 497.00K | 384.48K | 861.00 | 861.00 |
Source: https://incomestatements.info
Category: Stock Reports